Alpine Immune Sciences Inc
ALPN
ALPN was delisted on the 17th of May, 2024.
22 hedge funds and large institutions have $48M invested in Alpine Immune Sciences Inc in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 4 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
8% less funds holding
Funds holding: 24 → 22 (-2)
20% less capital invested
Capital invested by funds: $59.6M → $48M (-$11.6M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$78.3K |
| 2 |
Millennium Management
New York
|
+$74.8K |
| 3 |
State Street
Boston,
Massachusetts
|
+$70.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$40.9K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$36.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$2.1M |
| 2 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
-$110K |
| 3 |
Renaissance Technologies
New York
|
-$57K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$45K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$44.8K |
ALPN Hedge Fund Activity: Q3 2018 in Review
22 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q3 2018, worth a combined $48M — down 20% from $59.6M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ALPN and 2 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $78.3K. The largest seller was Deerfield Management, cutting an estimated $2.1M.
- 22 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q3 2018, down from 24 in Q2 2018.
- Funds reported $48M of Alpine Immune Sciences Inc stock for Q3 2018, down 20% quarter-over-quarter.
- 2 funds opened new Alpine Immune Sciences Inc positions in Q3 2018 and 4 closed out, a net change of -2 holders.
- The largest Alpine Immune Sciences Inc buyer in Q3 2018 was Vanguard Group, an estimated $78.3K added.
- The largest Alpine Immune Sciences Inc seller in Q3 2018 was Deerfield Management, an estimated $2.1M sold.
Based on aggregated 13F filings for Q3 2018.